EUVIMEDEUVIMED entdecken
Crossref

Preclinical Development of a Tolerogenic Peptide From Glutamate Decarboxylase as a Candidate for Antigen-Specific Immunotherapy in Type 1 Diabetes

Sky T H Ng, Michael J Price iD, Naomi Richardson, Maher Nawaf, Alastair Copland, Heather B Streeter, Parth Narendran iD, David C Wraith iD

Diabetes · 2025

DOI: 10.2337/db23-0996 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2025. Verfasst von Sky T H Ng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, U.K. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glutamate Decarboxylase, Immunotherapy, Immune Tolerance. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Diabetes UK, Leona M. and Harry B. Helmsley Charitable Trust, Children's Liver Disease Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysregulation and loss of immune tolerance toward pancreatic β-cell autoantigens are features of type 1 diabetes (T1D). Until recently, life-long insulin injection was the only approved treatment for T1D, but it does not address the underlying disease pathology. The aim for antigen-specific immunotherapy (ASI) is to restore tolerance. ASI holds potential as a new therapeutic strategy for treating autoimmune diseases with well-characterized antigens. Peptide ASI using processing-independent CD4+ T-cell epitopes (PIPs) shows promising results in several autoimmune diseases. Here, we successfully applied the principles of PIP design to the T1D autoantigen glutamate decarboxylase 65 (GAD65). Peptides spanning GAD65 predicted to be pan–HLA-DR binding were selected. Peptide 10 (P10) displayed enriched responses in peripheral blood mononuclear cells from people with T1D. The minimal epitope of the P10 peptide was fine mapped using T-cell hybridomas generated from HLA-DRB1*04:01 transgenic mice. This minimal epitope, P10Sol, was demonstrated, using a novel activation-induced marker assay, to induce tolerance to the parent peptide in the transgenic mice. Finally, we show that GAD65 P10Sol PIP is recognized by CD4+ T cells from people with T1D who possess a range of HLA-DR alleles and, therefore, can be defined as a pan–DR-binding peptide with therapeutic potential. Article Highlights There are currently no approved antigen-specific immunotherapies (ASIs) for people with type 1 diabetes (T1D). We aimed to develop a peptide for ASI for T1D based on the T1D-associated auto-antigen glutamate decarboxylase 65 (GAD65). A minimal and soluble peptide derived from GAD65 was demonstrated to induce tolerance in an HLA transgenic mouse. Our data suggest this peptide derived from the GAD65 islet protein should be tested for therapeutic potential in people with T1D who have residual β-cell function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Glutamate DecarboxylaseImmunotherapyImmune ToleranceAnimalsMiceHumansMice, TransgenicEpitopes, T-LymphocyteAutoantigensCD4-Positive T-LymphocytesMice, Inbred NODFemale

Substanzen

Glutamate Decarboxylaseglutamate decarboxylase 2Epitopes, T-LymphocyteAutoantigens

Autor:innen und Institutionen

  • Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, U.K.

ORCID-Profile: Michael J Price, Parth Narendran, David C Wraith

Förderung

  • Diabetes UK
  • Leona M. and Harry B. Helmsley Charitable Trust
  • Children's Liver Disease Foundation

Zitieren

APA

Ng, S. T. H., Price, M. J., Richardson, N., Nawaf, M., Copland, A., Streeter, H. B., Narendran, P., & Wraith, D. C. (2025). Preclinical Development of a Tolerogenic Peptide From Glutamate Decarboxylase as a Candidate for Antigen-Specific Immunotherapy in Type 1 Diabetes. Diabetes. https://doi.org/10.2337/db23-0996

Vancouver

Ng STH, Price MJ, Richardson N, Nawaf M, Copland A, Streeter HB, et al. Preclinical Development of a Tolerogenic Peptide From Glutamate Decarboxylase as a Candidate for Antigen-Specific Immunotherapy in Type 1 Diabetes. Diabetes. 2025. doi:10.2337/db23-0996

BibTeX
@article{Ng2025,
  author = {Ng, Sky T H and Price, Michael J and Richardson, Naomi and Nawaf, Maher and Copland, Alastair and Streeter, Heather B and Narendran, Parth and Wraith, David C},
  title = {Preclinical Development of a Tolerogenic Peptide From Glutamate Decarboxylase as a Candidate for Antigen-Specific Immunotherapy in Type 1 Diabetes},
  journal = {Diabetes},
  year = {2025},
  doi = {10.2337/db23-0996}
}
Kostenlos starten →